Innovative Therapies

TIF Guide on COVID-19 Vaccinations & Therapeutic Drugs – The December Issue
Νέα

TIF Guide on COVID-19 Vaccinations & Therapeutic Drugs – The December Issue

During this last fortnight, experts have scrambled to gain an understanding of the new heavily mutated variant, what kind of symptoms and illness it can cause, and whether it undermines…
FDA Grants Priority Review to Luspatercept-aamt for Anemia in Adults With NTD β-Thalassaemia
Κλινικά Νέα

FDA Grants Priority Review to Luspatercept-aamt for Anemia in Adults With NTD β-Thalassaemia

The FDA has set a Prescription Drug User Fee Act (PDUFA) goal date of March 27, 2022. In addition, the European Medicines Agency (EMA) has validated the Type II variation…
Juggling Between The Cost And Value of New Therapies: Does Science Still Serve Patient Needs?
Press Releases

Juggling Between The Cost And Value of New Therapies: Does Science Still Serve Patient Needs?

In the aftermath of the withdrawal of Zynteglo, the first gene therapy for patients with β-thalassaemia, from Europe, TIF´s Executive Director, Dr Androulla Eleftheriou, reflects on the viability of the…
Coming Up This Thursday: Discussion On Access To Innovative Therapies – The Reblozyl Case
Νέα

Coming Up This Thursday: Discussion On Access To Innovative Therapies – The Reblozyl Case

After receiving numerous questions from patients regarding the innovative treatment for β-thalassaemia Reblozyl (luspatercept), approved for use in the US, Europe, and Canada, TIF proceeds to organise an interactive, online…
Live Webinar on Thalassemia: Advances in 2021 with Dr M.D. Cappellini
Νέα

Live Webinar on Thalassemia: Advances in 2021 with Dr M.D. Cappellini

The past decade has witnessed path-breaking advances with regard to novel therapeutic approaches of thalassaemia and, most significantly, phenomenal developments made in the direction of gene therapy of β- thalassaemia…
TIF’s Statement on Accessibility of Gene Therapy for Thalassaemia
Press Releases

TIF’s Statement on Accessibility of Gene Therapy for Thalassaemia

The Thalassaemia International Federation (TIF) expresses its disappointment about the outcome of the reimbursement negotiation process concerning gene therapy (Zynteglo™) for transfusion-dependent thalassaemia patients, announced last week. The Federation’s distress…
Clinical Trial Cleared for GPH101: The First Potentially Curative Sickle Cell Disease Therapy
Κλινικά Νέα

Clinical Trial Cleared for GPH101: The First Potentially Curative Sickle Cell Disease Therapy

The U.S. Food & Drug Administration (FDA) has cleared an investigational new drug (IND) application for the experimental gene editing therapy GPH101 by Graphite Bio to initiate a Phase 1/2…
EdiGene Announces Approval in China of its IND Application for CRISPR/Cas 9 Gene Editing Therapy ET-01 in β-thalassaemia
Νέα

EdiGene Announces Approval in China of its IND Application for CRISPR/Cas 9 Gene Editing Therapy ET-01 in β-thalassaemia

The Center for Drug Evaluation (CDE) of China‘s National Medical Products Administration (NMPA) has recently approved EdiGene’s application for ET-01, an investigational CRISPR-Cas9 gene editing therapy for patients with transfusion dependent β-thalassaemia. This marks the first…
What’s New In Clinical Trials for Thalassaemia and Sickle Cell Disease?
Κλινικά Νέα

What’s New In Clinical Trials for Thalassaemia and Sickle Cell Disease?

There is a lot of hustle and bustle in the scientific fields of thalassemia and sickle cell disease during the past few months, with many companies making remarkable progress in…
EdiGene Application of CRISPR/Cas 9 Gene-editing Therapy ET-01 For β-Thalassaemia Has Been Accepted For Review
Κλινικά Νέα

EdiGene Application of CRISPR/Cas 9 Gene-editing Therapy ET-01 For β-Thalassaemia Has Been Accepted For Review

Τhe Chinese biotechnology company EdiGene announced yesterday that the Center for Drug Evaluation (CDE) of China’s National Medical Products Administration (NMPA) has accepted for review the Company’s Investigational New Drug…
Back to top button